Since the marketing authorization of the monoclonal antibody infliximab in 1998, anti-tumor necrosis factor alpha (TNF-α) therapy has been added to the pharmacological arsenal for treatment of IBD. This evidence concerns the gene TNF and inflammatory bowel disease.